Biopharmaceutical company Odyssey Therapeutics successfully priced its initial public offering at the top of its range, raising $279 million in a strong debut that highlights the returning appetite for high-quality immunology platforms in 2026.
The Boston-based company sold 15.5 million shares at $18 each on Thursday, above its marketed range of $16 to $18. The upsized offering reflects robust demand from institutional investors for Odyssey’s focused approach to treating autoimmune and inflammatory diseases.
This marks another notable success in what has become a meaningful revival of the U.S. biotech IPO market this year, buoyed by expectations of a more predictable and innovation-friendly regulatory environment under President Donald Trump and anticipated shifts at the U.S. Food and Drug Administration.
Register for Tekedia Mini-MBA edition 20 (June 8 – Sept 5, 2026).
Register for Tekedia AI in Business Masterclass.
Join Tekedia Capital Syndicate and co-invest in great global startups.
Register for Tekedia AI Lab.
In recent weeks, several well-funded drug developers, including Seaport Therapeutics, Hemab Therapeutics, Alamar Biosciences, and weight-loss drug developer Kailera Therapeutics, have also gone public, signaling renewed access to public capital for promising biotech platforms.
Founded in 2021 by Dr. Gary D. Glick, Odyssey has rapidly established itself as one of the most heavily backed private biotech companies, raising approximately $726.5 million from more than 30 investors prior to its IPO. Glick, who serves as chairman and chief executive officer, brings significant credibility to the venture. He previously founded Scorpion Therapeutics, which was acquired by Eli Lilly in 2025 in a deal valued at up to $2.5 billion in cash, one of the largest takeouts in the targeted oncology space in recent memory.
Odyssey is developing novel therapies for autoimmune and inflammatory conditions, an area with substantial unmet medical need and strong commercial potential. Its lead candidate, OD-001, is currently in a mid-stage clinical trial for ulcerative colitis, one of the two primary forms of inflammatory bowel disease (IBD).
The company plans to use the IPO proceeds primarily to advance clinical development of OD-001 and support other general corporate purposes. IBD affects millions of patients worldwide and represents a multi-billion-dollar market, with significant room for new therapies that offer better efficacy, safety, or convenience than existing treatments.
Glick’s track record of building scientifically rigorous companies and successfully exiting them has clearly resonated with investors. Odyssey’s ability to attract substantial private capital and command a strong IPO valuation underscores confidence in both its science and leadership team.
J.P. Morgan, TD Cowen, and Cantor served as the lead underwriters for the offering. Odyssey is expected to begin trading on Nasdaq under the ticker symbol “ODTX” on Friday.
The strength of Odyssey’s debut adds to growing optimism that the biotech financing window is reopening after several challenging years. Improved sentiment around regulatory clarity, potential policy tailwinds for innovation, and strong performance by several recent IPOs have encouraged more companies to test the public markets.
Investors appear particularly interested in platforms with experienced founders, differentiated science, and assets already in clinical development. Odyssey fits this profile well, entering the market with a lead program in mid-stage trials and a seasoned management team.
However, the broader environment remains selective. Only companies with compelling data, strong balance sheets post-IPO, and clear paths to value inflection are likely to succeed. Odyssey’s substantial pre-IPO funding gives it a solid cash runway, reducing immediate financing risk and allowing management to focus on clinical execution.
The IPO also highlights continued investor appetite for immunology and inflammation plays. With growing understanding of disease pathways and advances in precision medicine, this sector has delivered several high-profile successes in recent years, attracting both specialist healthcare investors and generalist funds seeking growth opportunities.
Odyssey’s success in the ongoing Phase 2 trial of OD-001, combined with disciplined capital allocation, is expected to position the company for further upside. The IBD space remains competitive, but meaningful innovation continues to be rewarded. However, the offering values Odyssey at a significant premium, reflecting both excitement around its pipeline and confidence in Glick’s ability to deliver.